NPPA sets retail prices of 74 drug formulations; BP, Diabetes Medicines See also Pricing

The National Pharmaceutical Pricing Authority (NPPA) said Monday it has set the retail prices of 74 formulations, including drugs to treat high blood pressure and diabetes.

“The National Pharmaceutical Pricing Authority (NPPA) has set prices under the Drugs (Price Control) Order, 2013, based on the decision of the 109th authority meeting held on Feb. 21, 2023,” a notice from the NPPA said on Monday.

The Drug Price Regulator has set the price of one tablet of Dapagliflozin Sitagliptin and Metformin Hydrochloride (Extended Release Tablets) at Rs 27.75 through the notice. The price of one tablet of antihypertensive medication Telmisartan and Bisoprolol Fumarate Tablets is set at Rs 10.92.

The NPPA said it has also revised the price ceiling of 80 planned formulations (NLEM 2022), including those for the treatment of epilepsy and neutropenia.

The ceiling price of one tablet (200mg) of sodium valproate is set at Rs 3.20. Similarly, the ceiling price of Filgrastim Injection (one vial) is set at Rs 1,034.51.

The price of one tablet of Hydrocortisone (20mg), a steroid, is set at Rs 13.28.

According to a separate notice on Monday, the NPPA also revised the price cap of 80 scheduled formulations under Drugs (Prices Control) Order, 2013 (NLEM 2022) based on the decision of the Authority’s 109th meeting on Feb. 21.

The NPPA is mandated to set/review the prices of controlled bulk drugs and formulations and to enforce prices and availability of the drugs in the country.

It also monitors the prices of deregulated drugs to keep them at reasonable levels. The regulator implements and enforces the provisions of the Drugs (Prices Control) Order. It is also tasked with recovering amounts overcharged by manufacturers for controlled medicines from consumers.

(With input from PTI)

Read all the latest business news here